Search

Insmed

Fechado

SetorSaúde

123.8 0.1

Visão Geral

Variação de preço das ações

24h

Atual

Mín

122.23

Máximo

125.95

Indicadores-chave

By Trading Economics

Rendimento

150M

-13M

Vendas

120M

425M

EPS

-0.52

Margem de lucro

-3.112

Funcionários

1,664

EBITDA

150M

14M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+59.99% upside

Dividendos

By Acuity

Próximos Ganhos

29 de out. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

6.7B

28B

Abertura anterior

123.7

Fecho anterior

123.8

Sentimento de Notícias

By Acuity

64%

36%

303 / 340 Ranking em Healthcare

Insmed Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de ago. de 2026, 19:56 UTC

Event
Social Media
News

Insmed Inc. received approval for Brinsupri in Japan, the first therapy for non-cystic fibrosis bronchiectasis. Shares are lower amid news of a major shareholder's stock sale.

20 de ago. de 2026, 20:02 UTC

Insmed Inc shares are lower amid a significant decline in the Biotechnology sector. Trading volume is unusually high, with no specific news identified.

19 de ago. de 2026, 23:41 UTC

Insmed Inc. shares are higher in after-market trading, reflecting notable volatility with significant fluctuations since Wednesday's close.

17 de ago. de 2026, 20:02 UTC

Social Media
News

Insmed shares rise as Duquesne Capital reports $151.9 million stake and Mizuho sets a $192 price target amid ongoing product launches.

14 de ago. de 2026, 19:36 UTC

Insmed Inc shares are lower, reflecting broader market sentiment after a reported decline in retail sales. The stock has closed lower for four consecutive sessions.

13 de ago. de 2026, 19:51 UTC

News
Social Media

Insmed shares are lower despite raised earnings estimates and target price increases from HC Wainwright and Wells Fargo during Thursday's session.

12 de ago. de 2026, 19:36 UTC

News

Insmed shares are trading lower despite multiple analysts issuing positive ratings and target price increases, including BMO's $192.00 and Cantor Fitzgerald's $235.00.

11 de ago. de 2026, 21:16 UTC

Insmed Inc. shares moved slightly lower during after-market hours, remaining near the upper end of their one-month range and above the 20-day moving average.

10 de ago. de 2026, 23:41 UTC

News

Analysts adjusted price targets for Insmed Inc. after recent evaluations. Shares are higher in after-market trading, reflecting positive sentiment amid these actions.

7 de ago. de 2026, 21:21 UTC

Insmed Inc shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

6 de ago. de 2026, 23:56 UTC

Insmed Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

5 de ago. de 2026, 23:22 UTC

Insmed Inc shares are higher in after-market trading, reflecting positive momentum amid a significant drop in crude oil prices and easing inflation concerns.

3 de ago. de 2026, 19:16 UTC

Insmed Inc shares are lower today, marking the seventh consecutive session of declines. No specific company news was identified to explain the movement.

31 de jul. de 2026, 20:06 UTC

Insmed Inc. shares are lower, continuing a seven-session decline amid rising Treasury yields and crude oil prices, with no specific company news identified.

30 de jul. de 2026, 21:16 UTC

Insmed Inc shares are higher in after-market trading, recovering from earlier losses. The stock rose to a high since Thursday's close.

28 de jul. de 2026, 19:26 UTC

Insmed Inc shares are lower today, with no specific news identified. Broader market sentiment is bearish, influenced by declines in Asian markets.

27 de jul. de 2026, 23:41 UTC

Insmed Inc's shares are higher in after-market hours, rebounding from a lower regular session. No specific news was identified for this price movement.

24 de jul. de 2026, 23:46 UTC

Insmed Inc shares are lower in after-market hours, continuing recent trends. The stock remains near the lower end of its one-month trading range.

22 de jul. de 2026, 19:11 UTC

Social Media

Insmed shares are lower despite Cantor Fitzgerald's "Overweight" rating and $235 price target, following positive updates on inhalation powder TPIP.

21 de jul. de 2026, 17:41 UTC

Social Media
News

BMO Capital initiated coverage on Insmed Inc with an Outperform rating and a $192 price target, contributing to the stock's upward movement.

20 de jul. de 2026, 19:16 UTC

News
Social Media

Insmed Inc's shares are lower today amid declines in the Biotechnology sector. Social media highlights positive sentiment around TPIP data and its strong pipeline.

Comparação entre Pares

Variação de preço

Insmed Previsão

Preço-alvo

By TipRanks

59.99% parte superior

Previsão para 12 meses

Média 201.22 USD  59.99%

Máximo 243 USD

Mínimo 169 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Insmed - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

19 ratings

19

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

303 / 340 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
help-icon Live chat